Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and Aspirin for Prevention of Stroke and Death (THALES) trial: Rationale and design
Univ Texas Austin, Dell Med Sch, 1501 Red River, Austin, TX 78712 USA.
Hop Xavier Bichat, Dept Neurol, Paris, France.
AstraZeneca, Global Med Dev, Gothenburg, Sweden.
George Washington Univ, Biostat Ctr, Washington, DC USA.
Vise andre og tillknytning
2019 (engelsk)Inngår i: International Journal of Stroke, ISSN 1747-4930, E-ISSN 1747-4949, Vol. 14, nr 7, s. 745-751Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Rationale

In patients with acute cerebral ischemia, the rate of stroke, myocardial infarction, or death during 90 days was reported to be non-significantly lower with ticagrelor compared with aspirin, with no increase in major hemorrhage. Dual antiplatelet therapy may be more effective in this setting.

Aim

To investigate whether ticagrelor combined with aspirin are superior to aspirin alone in preventing stroke or death in patients with non-severe, non-cardioembolic ischemic stroke or high-risk transient ischemic attack.

Design

The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and Aspirin for Prevention of Stroke and Death (THALES) trial is a randomized, placebo-controlled, double-blind, event-driven study. Patients will be randomized within 24 h of onset of acute ischemic symptoms. THALES is expected to randomize 13,000 at ∼450 sites worldwide, to collect 764 primary outcome events. Study treatments are ticagrelor 180 mg loading dose on day 1, then 90 mg twice daily on days 2–30, or matching placebo. All patients will also receive open-label aspirin 300–325 mg on day 1, then 75–100 mg once daily on days 2–30.

Study outcomes

The primary efficacy outcome is time to the composite endpoint of stroke or death through 30-day follow-up. The primary safety outcome is time to first severe bleeding event.

Discussion

The THALES trial will provide important information about the benefits and risks of dual antiplatelet therapy with ticagrelor and aspirin in patients with acute cerebral ischemia in a global setting (funding: AstraZeneca)

sted, utgiver, år, opplag, sider
2019. Vol. 14, nr 7, s. 745-751
Emneord [en]
Stroke, TIA, cerebral ischemia, antiplatelet, ticagrelor, aspirin
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-397137DOI: 10.1177/1747493019830307ISI: 000492996800013PubMedID: 30747613OAI: oai:DiVA.org:uu-397137DiVA, id: diva2:1373798
Forskningsfinansiär
AstraZenecaTilgjengelig fra: 2019-11-28 Laget: 2019-11-28 Sist oppdatert: 2019-11-28bibliografisk kontrollert

Open Access i DiVA

fulltekst(2522 kB)30 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 2522 kBChecksum SHA-512
fae4a51887b39eb7fe2898fd570bd18c84d8e68ee567dbddfe1dfcca77b9fe7c716c25cb58b9dc553208660ddabc9fcb5c4d53c38c1d8455213b004aa1d8b7be
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMed

Søk i DiVA

Av forfatter/redaktør
James, Stefan
Av organisasjonen
I samme tidsskrift
International Journal of Stroke

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 30 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 27 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf